Bayer for ProfessionalsYour Resource Portal

PP-PF-OTH-GB-0055 | February 2024

Explore Bayer Products

Nephrology & Cardiology Products

Xarelto®

Protect what matters most for your eligible cardiovascular patients

Xarelto Prescribing Information

PP-XAR-GB-3601, February 2024

Kerendia®▼ (finerenone)

Product Page

Kerendia (finerenone) UK Prescribing Information

PP-KER-GB-0468, March 2024

Oncology Products

Stivarga® (regorafenib)

In mCRC

Stivarga Prescribing Information

PP-STI-GB-0204, February 2024

Nexavar® (sorafenib) & Stivarga® (regorafenib)

In HCC

Nexavar Prescribing Information

Stivarga Prescribing Information

PP-NEX-GB-0211, February 2024

Xofigo®▼ (radium-223 dichloride)

In mCRPC

Xofigo Prescribing Information

PP-XOF-GB-0460, February 2024

NUBEQA®▼ (darolutamide)

In nmCRPC and mHSPC

NUBEQA GB Prescribing Information

NUBEQA NI Prescribing Information

PP-NUB-GB-1317, February 2024

Women's Health Products

Qlaira® (Estradiol valerate/dienogest)

Qlaira Prescribing information

PP-PF-WHC-IUS-GB-0025, February 2024

Jaydess® ▼ (13.5mg levonorgestrel)

Jaydess Prescribing Information

PP-PF-WHC-IUS-GB-0026 February 2024

Kyleena® 19.5mg levonorgestrel

Kyleena® Prescribing Information

PP-PF-WHC-IUS-GB-0018, February 2024

Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.

Further information is available on the "contact" tab at www.bayer.co.uk.